SCHEMBL9109006

SCHEMBL9109006

O=C(O)C(Cc1ccc(Cl)c(Cl)c1)c1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
POLB P06746 2/20 0.46
KMT2A Q03164 3/20 0.44
PNMT P11086 1/20 0.44
MEN1 O00255 2/20 0.42
PPARG P37231 2/20 0.42
PPARA Q07869 2/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
CYP2D6 P10635 1/20 0.42
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
EPHX1 P07099 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CHRM1 P11229 1/20 0.41
SLC6A2 P23975 1/20 0.41
PDE4A P27815 1/20 0.41
EPHX2 P34913 1/20 0.41
ADRA1A P35348 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6003758 0.89 FPR2 (0.51) CYP2C19POLBKMT2APNMTMEN1
SCHEMBL6005718 0.89 FPR2 (0.51) CYP2C19POLBKMT2APNMTMEN1
SCHEMBL6005310 0.89 FPR2 (0.51) CYP2C19POLBKMT2APNMTMEN1
SCHEMBL6006575 0.88 KMT2A (0.49) KMT2APNMTPPARGPPARAPTGS1
SCHEMBL6005803 0.88 PPARA (0.50) CYP2C9CYP2C19PNMTPPARGPPARA
SCHEMBL6004995 0.85 PNMT (0.41) CYP2C9CYP2C19POLBKMT2APNMT
SCHEMBL9109224 0.82 CYP2C9 (0.50) CYP2C9CYP2C19POLBKMT2AMEN1
SCHEMBL8673949 0.81 PPARG (0.48) CYP2C9CYP2C19POLBKMT2APNMT
SCHEMBL3370947 0.80 EPHX1 (0.56) CYP2C9CYP2C19POLBPPARGPPARA
SCHEMBL605909 0.80 P4HTM (0.56) CYP2C9CYP2C19POLBKMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2646027-B1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN INC (US) 2014-10-15 EP disclosed
US-8697733-B2 Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2014-04-15 US disclosed
US-20130338195-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. 2013-12-19 US disclosed
US-8492410-B2 Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2013-07-23 US disclosed
US-20130150411-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-06-13 US disclosed
US-8399492-B2 Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2013-03-19 US disclosed
US-20120142736-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150411-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 CYP2C9 4187/4885CYP2C19 3484/4885POLB 4644/4885
US-20130338195-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 CYP2C9 4187/4885CYP2C19 3484/4885POLB 4644/4885
US-20120142736-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 CYP2C9 4187/4885CYP2C19 3484/4885POLB 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.